Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > 2 weeks: It’s all it took for Merck to get AA
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(297)
•••
Comment by FGPstockon Dec 07, 2022 10:13pm
163 Views
Post# 35158038

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA
Eog, I hope you are right. The statements are only a few months apart and correspond with TLT taking the stateme nt out of their financials.

Below is a statement from your friend Ben sayin revenue in jan 2023. Who do you trust, someone like ben who changes his opinion daily, or someone who has more access to tlt management than any of us...


ScienceFirst (7869)
April 19, 2022 - 06:38 PM
281 Reads
Post# 34614803

Accelerated Approval would allow revenues early 2023

TLT is expecting commercial revenues Jan. 2023.  Right after Breakthrough designation.

That could come from only 2 sources;

- upfront payment from a jv after Breakthrough designation
- Accelerated Approval program that allows revenues until the completion of a clinical trial (see below)

My take is that on top of Breakthrough designation, TLT expects to also qualify for the Accelerated Approval program as our drug has all that the FDA wants in a drug.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities